Shenzhen Neptune Bioengineering Co., Ltd. is a listed company. Shenzhen Neptune Bioengineering Co., Ltd. was founded in 1992. It is a large listed pharmaceutical company (stock code: 000078) that focuses on pharmaceutical research and development, pharmaceutical business and pharmaceutical industry. Nearly thirty years have passed since its establishment. The company has always stood at the forefront of the biopharmaceutical industry, constantly optimizing the industrial chain, while focusing on internal growth and external expansion. Its operating performance has achieved steady growth for many consecutive years.
The "Neptune" brand has far-reaching influence in China's medical and health field, and has ranked first in the brand value evaluation of China's pharmaceutical industry for 17 consecutive years. As of 2020, the brand value of "Aquaman" has reached an astonishing 91.568 billion yuan. Behind this achievement is Neptune Biotech's strong independent research and development and technological innovation capabilities, which is also the core driving force for the company's sustained and rapid development. Relying on national-level corporate technology centers and postdoctoral workstations, Neptune Biotech has built a unique pharmaceutical R&D system, taking scientific and technological innovation as the forerunner to lead the internationalization process of pharmaceutical R&D.
To date, Neptune Biotechnology has applied for more than 190 patents and has obtained 105 patent authorizations. At the same time, there are multiple first-class innovative drugs in different stages of clinical research, and clinical research is being conducted simultaneously in the United States. .